AU2006336468B2 - Method of expressing proteins with disulfide bridges - Google Patents

Method of expressing proteins with disulfide bridges Download PDF

Info

Publication number
AU2006336468B2
AU2006336468B2 AU2006336468A AU2006336468A AU2006336468B2 AU 2006336468 B2 AU2006336468 B2 AU 2006336468B2 AU 2006336468 A AU2006336468 A AU 2006336468A AU 2006336468 A AU2006336468 A AU 2006336468A AU 2006336468 B2 AU2006336468 B2 AU 2006336468B2
Authority
AU
Australia
Prior art keywords
protein
thioredoxin
disintegrin
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006336468A
Other languages
English (en)
Other versions
AU2006336468A2 (en
AU2006336468A1 (en
Inventor
Frances Markland
Radu Minea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California
Original Assignee
University of Southern California
Pivotal Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California, Pivotal Biosciences Inc filed Critical University of Southern California
Publication of AU2006336468A1 publication Critical patent/AU2006336468A1/en
Assigned to UNIVERSITY OF SOUTHERN CALIFORNIA, PIVOTAL BIOSCIENCES, INC. reassignment UNIVERSITY OF SOUTHERN CALIFORNIA Alteration of Name(s) of Applicant(s) under S113 Assignors: UNIVERSITY OF SOUTHERN CALIFORNIA
Publication of AU2006336468A2 publication Critical patent/AU2006336468A2/en
Application granted granted Critical
Publication of AU2006336468B2 publication Critical patent/AU2006336468B2/en
Assigned to UNIVERSITY OF SOUTHERN CALIFORNIA reassignment UNIVERSITY OF SOUTHERN CALIFORNIA Request for Assignment Assignors: PIVOTAL BIOSCIENCES, INC., UNIVERSITY OF SOUTHERN CALIFORNIA
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006336468A 2005-02-11 2006-02-09 Method of expressing proteins with disulfide bridges Ceased AU2006336468B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65252905P 2005-02-11 2005-02-11
US60/652,529 2005-02-11
PCT/US2006/004413 WO2007086879A2 (en) 2005-02-11 2006-02-09 Method of expressing proteins with disulfide bridges

Publications (3)

Publication Number Publication Date
AU2006336468A1 AU2006336468A1 (en) 2007-08-02
AU2006336468A2 AU2006336468A2 (en) 2010-04-29
AU2006336468B2 true AU2006336468B2 (en) 2012-04-12

Family

ID=38309637

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006336468A Ceased AU2006336468B2 (en) 2005-02-11 2006-02-09 Method of expressing proteins with disulfide bridges

Country Status (7)

Country Link
US (4) US7754850B2 (cg-RX-API-DMAC10.html)
EP (2) EP2634252B1 (cg-RX-API-DMAC10.html)
JP (1) JP2008536479A (cg-RX-API-DMAC10.html)
CN (1) CN101535492A (cg-RX-API-DMAC10.html)
AU (1) AU2006336468B2 (cg-RX-API-DMAC10.html)
CA (1) CA2597647A1 (cg-RX-API-DMAC10.html)
WO (1) WO2007086879A2 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
US8008256B2 (en) 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US8470554B2 (en) * 2008-12-22 2013-06-25 St. Jude Children's Research Hospital Prokaryotic expression of soluble, active Dkk
CA2789679A1 (en) 2010-02-11 2011-08-18 University Of Southern California Modified adam disintegrin domain polypeptides and uses thereof
CN102154336A (zh) * 2011-01-25 2011-08-17 国家海洋局第三海洋研究所 嗜酸硫化芽孢杆菌硫氧还蛋白还原酶基因及其重组蛋白
EP2527424A1 (en) * 2011-05-26 2012-11-28 Richter-Helm Bio Tec GmbH & Co. KG Recombinant expression of soluble Interferon
WO2013076580A2 (en) * 2011-11-23 2013-05-30 Bioven 3 Limited Recombinant proteins and their therapeutic uses
US20170054032A1 (en) 2015-01-09 2017-02-23 SanDisk Technologies, Inc. Non-volatile memory having individually optimized silicide contacts and process therefor
CN105039377A (zh) * 2015-08-24 2015-11-11 武汉真福医药股份有限公司 溶栓酶基因qk-02的表达方法及专用表达载体和工程菌
WO2017083699A1 (en) * 2015-11-13 2017-05-18 University Of Southern California Radiolabeled disintegrins as brachytherapy agents
KR101678393B1 (ko) 2016-08-25 2016-12-06 (주)넥스젠바이오텍 피부 세포 증식 효과가 증가한 전갈독 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선, 피부 탄력 증대 및 항노화 화장료 조성물
US10258567B1 (en) 2016-11-17 2019-04-16 Grace Procurements Llc Vaginal probiotic products and related processes
CN107384934A (zh) * 2017-08-18 2017-11-24 安徽安科生物工程（集团）股份有限公司 重组人干扰素α2b的制备方法
US11169583B2 (en) * 2018-08-07 2021-11-09 Western Digital Technologies, Inc. Methods and apparatus for mitigating temperature increases in a solid state device (SSD)
EP3856760A1 (en) * 2018-09-25 2021-08-04 AbSci, LLC Protein purification methods
IL282875B2 (en) * 2018-11-08 2026-05-01 Sutro Biopharma Inc E. coli strains with oxygenated cytoplasm
US12351850B2 (en) 2020-04-30 2025-07-08 Sutro Biopharma, Inc. Methods of producing full-length antibodies using E. coli
CN114107353B (zh) * 2021-10-29 2024-07-23 成都佩德生物医药有限公司 一种高效表达多肽毒素的质粒及其制备方法与应用
EP4361172A3 (en) 2022-10-27 2024-05-29 Science4Beauty Sp. z o.o. Expression vector for recombinant u-conotoxin tiiia or tiiialamut expression in e.coli
CN117756949B (zh) * 2024-02-21 2024-10-15 中国人民解放军军事科学院军事医学研究院 一种正痘病毒属融合抗原及应用
CN120118913B (zh) * 2025-05-14 2025-09-02 中国科学院苏州纳米技术与纳米仿生研究所 一种编码人防御素的核酸分子及制备人防御素方法和应用

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610879A (en) 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
US5066592A (en) 1988-03-08 1991-11-19 Temple University Of The Commonwealth System Of Higher Education Trigramin - a platelet aggregation inhibiting polypeptide
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5278324A (en) 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5250683A (en) 1991-09-23 1993-10-05 Florida State University Certain substituted taxanes and pharmaceutical compositions containing them
US5227400A (en) 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5272171A (en) 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US5248796A (en) 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
US5254580A (en) 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6080569A (en) 1993-06-24 2000-06-27 Merck & Co., Inc. Adenovirus vectors generated from helper viruses and helper-dependent vectors
US5814609A (en) * 1993-10-22 1998-09-29 University Of Southern California Compositions containing a disintegrin and methods for its use in preventing metastasis and other conditions
US6710030B1 (en) * 1993-10-22 2004-03-23 University Of Southern California Contortrostain (CN) and methods for its use in preventing metastasis and other conditions
US20030186884A1 (en) * 2000-06-08 2003-10-02 Markland Francis S. Contortrostatin (CN) and methods for its use in preventing metastasis and other conditions
US7220724B2 (en) * 1993-10-22 2007-05-22 University Of Southern California Contortrostatin CN and methods for its use in preventing metastasis and other conditions
US5731288A (en) * 1993-10-22 1998-03-24 University Of Southern California Compositions containing contortrostatin and methods for the use thereof
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
FR2725726B1 (fr) 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
US5641665A (en) 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
AU695762B2 (en) 1995-05-22 1998-08-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Retrovirus vectors derived from avian sarcoma leukosis viruses permitting transfer of genes into mammalian cells and therapeutic uses thereof
WO1998021350A1 (en) 1996-11-13 1998-05-22 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US6660758B1 (en) 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6034072A (en) 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
DE19713213A1 (de) 1997-03-28 1998-10-01 Ruebben Alexander Dr Med Metallstent zur verlängerten Offenhaltung von Hohlorganen
AUPO742497A0 (en) * 1997-06-18 1997-07-10 N.J. Phillips Pty. Limited An applicator
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2290993T3 (es) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
DE19820599A1 (de) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19826988A1 (de) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
CA2343716C (en) 1998-09-29 2013-01-22 The University Of Southern California Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions
DE19848306A1 (de) 1998-10-14 2000-04-20 Schering Ag Verfahren zur Herstellung von Epothilon B und Derivaten sowie Zwischenprodukte für dieses Verfahren
US6440944B2 (en) 1998-10-16 2002-08-27 Genvec, Inc. Methods of administering adenoviral vectors
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
BR9916833A (pt) 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
EE200100422A (et) 1999-02-11 2002-12-16 Schering Aktiengesellschaft Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
EE200100431A (et) 1999-02-18 2002-12-16 Schering Aktiengesellschaft 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
US6406722B1 (en) 1999-02-18 2002-06-18 Robert G. Gallaher Method of treating viral infections and lesions with taxane compounds
JP3012931B1 (ja) * 1999-02-26 2000-02-28 工業技術院長 Ｓｐａｒｃ融合タンパク質およびその製造方法
US6387664B1 (en) * 1999-02-26 2002-05-14 Secretary Of Agency Of Industrial Science And Technology Sparc fusion protein and method for producing the same
US7125893B1 (en) 1999-04-30 2006-10-24 Schering Ag 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
US6878699B1 (en) 1999-05-21 2005-04-12 University Of Hawaii Taccalonolide microtubule stabilizing agents
US20050042275A1 (en) 1999-08-04 2005-02-24 Jean-Claude Sonntag Epothilone compositions
US6294374B1 (en) 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
WO2001041791A1 (en) 1999-12-10 2001-06-14 The University Of Southern California Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
DE10020517A1 (de) 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US6489314B1 (en) 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6998256B2 (en) 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US20020045609A1 (en) 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
US6638742B1 (en) 2000-07-07 2003-10-28 University Of Portland Methods for obtaining taxanes
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002221693A1 (en) 2000-10-16 2002-04-29 Morphochem Ag Epothilone synthesis components iii and iv: asymmetrically substituted acyloins and acyloin derivatives, method for the production thereof and method for the production of epithilone b, d and epothilone derivatives
WO2002042432A2 (en) 2000-11-22 2002-05-30 Novartis Ag Epothilone resistant cell lines
CA2436326C (en) 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
SK8552003A3 (en) 2001-01-25 2004-06-08 Bristol Myers Squibb Co Parenteral formulation containing epothilone analogs
DE60225666T2 (de) 2001-01-25 2009-04-16 Bristol-Myers Squibb Co. Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
US20030004338A1 (en) 2001-02-01 2003-01-02 Li Wen Sen Process for the preparation of epothilone analogs
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EE200300397A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaadid refraktaarsete kasvajate raviks
IL156988A0 (en) 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
PL207197B1 (pl) 2001-02-27 2010-11-30 Novartis Ag Połączenie obejmujące inhibitor przekazywania sygnału i pochodną epotylonową, kompozycja farmaceutyczna zawierająca to połączenie oraz zastosowanie połączenia
ATE554756T1 (de) 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
EP1372650B1 (en) 2001-03-19 2008-11-19 Novartis AG Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US6906188B2 (en) 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
US20030023082A1 (en) 2001-05-15 2003-01-30 Gary Ashley Epothilone derivatives and methods for making and using the same
US6800653B2 (en) 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
DE10138347A1 (de) 2001-08-03 2003-02-27 Schering Ag Geschützte 3,5-Dihydroxy-2,2-dimethyl-valeronitrile für die Synthese von Epothilonen- und Derivaten und Verfahren zur Herstellung
ES2315399T3 (es) 2001-08-23 2009-04-01 Novartis Ag Analogos de epotilona ciclobutilo y ciclopropilo.
US20030186334A1 (en) 2001-09-12 2003-10-02 Temple University - Of The Commonwealth System Of Higher Education KTS-disintegrins
WO2003029195A1 (en) 2001-09-28 2003-04-10 Sumika Fine Chemicals Co., Ltd. Intermediates for epothilone derivative and process for producing these
US7070964B2 (en) 2001-11-15 2006-07-04 Kosan Biosciences Incorporated Epothilone compounds and methods for making the same
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
DE10164592A1 (de) 2001-12-21 2003-07-03 Schering Ag C1-C6-Epothilon-Fragmente und Verfahren für die Herstellung von C1-C6-Fragmenten von Epothilonen und deren Derivaten
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
US6900331B2 (en) 2002-03-01 2005-05-31 University Of Notre Dame Derivatives of epothilone B and D and synthesis thereof
AU2003218110A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
CN1649585A (zh) 2002-05-01 2005-08-03 诺瓦提斯公司 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
AU2003296878A1 (en) 2002-05-20 2004-12-13 Kosan Biosciences, Inc. Methods to administer epothilone d
US7799561B2 (en) 2002-06-12 2010-09-21 Sigma-Aldrich, Co. Affinity peptides and method for purification of recombinant proteins
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
ES2297189T3 (es) 2002-08-02 2008-05-01 Novartis Ag Derivados de epotilona.
US7053201B2 (en) 2002-08-30 2006-05-30 National Defense Medical Center Nucleic acid molecules and polypeptides related to h-ADAM7
HRP20050278A2 (en) 2002-09-23 2005-10-31 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
GB0230024D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
JP2004217535A (ja) 2003-01-10 2004-08-05 Nec Soft Ltd 蛋白質ｔｒｉｍｅｓｔａｔｉｎの結晶化、構造座標の決定、構造座標の使用
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
AU2004275881A1 (en) 2003-09-25 2005-04-07 Tapestry Pharmaceuticals, Inc. 9,10-alpha,alpha-OH-taxane analogs and methods for production thereof
AU2005316217A1 (en) 2004-12-17 2006-06-22 Memorial Sloan Kettering Cancer Center Regulation of metalloprotease cleavage of cell surface proteins
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
US9265933B2 (en) 2005-09-08 2016-02-23 Massachusetts Eye And Ear Infirmary Cochlear implants containing biological cells and uses thereof
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
US8852290B2 (en) 2007-03-02 2014-10-07 Doheny Eye Institute Biocompatible implants and methods of making and attaching the same
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2010093468A1 (en) 2009-02-12 2010-08-19 University Of Southern California Bioadhesive patch for sutureless closure of soft tissue
CA2789679A1 (en) 2010-02-11 2011-08-18 University Of Southern California Modified adam disintegrin domain polypeptides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOURA-DA-SILVA, AM et al., Archives of Biochemistry and Biophysics, 1999, Vol. 369, No. 2, pages 295-301 *

Also Published As

Publication number Publication date
WO2007086879A3 (en) 2009-06-11
CA2597647A1 (en) 2007-08-02
AU2006336468A2 (en) 2010-04-29
US8338365B2 (en) 2012-12-25
EP2634252B1 (en) 2018-12-19
US8685668B2 (en) 2014-04-01
US20060246541A1 (en) 2006-11-02
AU2006336468A1 (en) 2007-08-02
US20120301453A1 (en) 2012-11-29
EP2634252A2 (en) 2013-09-04
US7754850B2 (en) 2010-07-13
CN101535492A (zh) 2009-09-16
EP2634252A3 (en) 2013-11-13
US20110097388A1 (en) 2011-04-28
EP1856255A4 (en) 2010-01-27
JP2008536479A (ja) 2008-09-11
US8110542B2 (en) 2012-02-07
US20130345399A1 (en) 2013-12-26
WO2007086879A2 (en) 2007-08-02
EP1856255A2 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
US8338365B2 (en) Inhibiting integrin receptor binding with non-native monomeric disintegrin or monomeric disintegrin domains
CA2313248C (en) Process for the production of naturally folded and secreted proteins by co-secretion of molecular chaperones
Sargent et al. Reassignment of the gene encoding the Escherichia coli hydrogenase 2 small subunit: identification of a soluble precursor of the small subunit in a hypB mutant
Jonda et al. Complementation of DsbA deficiency with secreted thioredoxin variants reveals the crucial role of an efficient dithiol oxidant for catalyzed protein folding in the bacterial periplasm
KR960002869B1 (ko) 이황화 결합을 갖는 분비된 단백질의 수율을 증가시키는 방법
EP1002111A2 (en) Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
Minea et al. Development of a novel recombinant disintegrin, contortrostatin, as an effective anti-tumor and anti-angiogenic agent
JP3691722B2 (ja) 自然に折りたたまれかつ分泌されるタンパク質を生産するための方法
US8802394B2 (en) Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2007127735A2 (en) Prokaryotic host cells for expressing proteins rich in disulfide bonds
KR101634078B1 (ko) 봉입체 형성 단백질의 제조방법
Wang et al. A unique approach for high level expression and production of a recombinant cobra neurotoxin in Escherichia coli
EP3992286A1 (en) Non-toxic protease having improved productivity
HK1189033A (en) Method of expressing proteins with disulfide bridges
HK1189033B (en) Method of expressing proteins with disulfide bridges
AU2002221815B2 (en) Methods for large scale production of recombinant DNA-derived tPA or K2S molecules
Peisley et al. High-level expression of a soluble and functional fibronectin type II domain from MMP-2 in the Escherichia coli cytoplasm for solution NMR studies
JPWO2005030956A1 (ja) ＯｍｐＴプロテアーゼ変異体を用いたポリペプチドの切断方法
Bonnecaze et al. Laura Segatori
Segatori Structure, function, and engineering of disulfide bond isomerization in Escherichia coli
EP2097520A1 (en) A method for producing n-terminal methioine free polypeptides in microbial host cells
Zhan Genetic and biochemical studies of disulfide bond isomerization in Escherichia coli
Qiu Genetic and biochemical analysis of disulfide bond isomerization in Escherichia coli
Arredondo Engineering and characterization of disulfide bond isomerases in Escherichia coli

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT( S) FILED 09 MAR 2010

PC1 Assignment before grant (sect. 113)

Owner name: UNIVERSITY OF SOUTHERN CALIFORNIA

Free format text: FORMER APPLICANT(S): PIVOTAL BIOSCIENCES, INC.; UNIVERSITY OF SOUTHERN CALIFORNIA

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired